159 related articles for article (PubMed ID: 8918978)
21. Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines.
Chetrite GS; Kloosterboer HJ; Philippe JC; Pasqualini JR
Anticancer Res; 1999; 19(1A):269-75. PubMed ID: 10226553
[TBL] [Abstract][Full Text] [Related]
22. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer.
Pasqualini JR; Schatz B; Varin C; Nguyen BL
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):323-9. PubMed ID: 1580921
[TBL] [Abstract][Full Text] [Related]
23. Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells.
Pasqualini JR; Chetrite G
J Steroid Biochem Mol Biol; 2001 Jul; 78(1):21-4. PubMed ID: 11530280
[TBL] [Abstract][Full Text] [Related]
24. The selective estrogen enzyme modulator (SEEM) in breast cancer.
Chetrite GS; Pasqualini JR
J Steroid Biochem Mol Biol; 2001; 76(1-5):95-104. PubMed ID: 11384867
[TBL] [Abstract][Full Text] [Related]
25. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells.
MacIndoe JH
Endocrinology; 1988 Sep; 123(3):1281-7. PubMed ID: 2969800
[TBL] [Abstract][Full Text] [Related]
26. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines.
Pasqualini JR; Nguyen BL
Breast Cancer Res Treat; 1991 May; 18(2):93-8. PubMed ID: 1912612
[TBL] [Abstract][Full Text] [Related]
27. Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells.
Turgeon C; Gingras S; Carrière MC; Blais Y; Labrie F; Simard J
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):151-62. PubMed ID: 9699868
[TBL] [Abstract][Full Text] [Related]
28. Progestins and breast cancer.
Pasqualini JR
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():32-41. PubMed ID: 17943537
[TBL] [Abstract][Full Text] [Related]
29. Effect of the progestagen R5020 (promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47d human mammary cancer cells: correlation with progesterone receptor levels.
Pasqualini JR; Varin C; Nguyen BL
Cancer Lett; 1992 Sep; 66(1):55-60. PubMed ID: 1451096
[TBL] [Abstract][Full Text] [Related]
30. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
31. Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells.
Chetrite GS; Pasqualini JR
Horm Mol Biol Clin Investig; 2010 Dec; 3(2):417-24. PubMed ID: 25961213
[TBL] [Abstract][Full Text] [Related]
32. Control and expression of oestrone sulphatase activities in human breast cancer.
Pasqualini JR; Chetrite G; Nestour EL
J Endocrinol; 1996 Sep; 150 Suppl():S99-105. PubMed ID: 8943793
[TBL] [Abstract][Full Text] [Related]
33. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
Ayan D; Maltais R; Roy J; Poirier D
Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
[TBL] [Abstract][Full Text] [Related]
34. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells.
Chetrite G; Kloosterboer HJ; Pasqualini JR
Anticancer Res; 1997; 17(1A):135-40. PubMed ID: 9066643
[TBL] [Abstract][Full Text] [Related]
35. The SEEM: selective estrogen enzyme modulators in breast cancer.
Pasqualini JR; Ebert C; Chetrite GS
Gynecol Endocrinol; 1999 Dec; 13 Suppl 6():1-8. PubMed ID: 10862262
[TBL] [Abstract][Full Text] [Related]
36. Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone.
Ngueta AD; Roy J; Maltais R; Poirier D
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677690
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer.
Duncan L; Purohit A; Howarth NM; Potter BV; Reed MJ
Cancer Res; 1993 Jan; 53(2):298-303. PubMed ID: 8417823
[TBL] [Abstract][Full Text] [Related]
38. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Pasqualini JR; Chetrite G; Blacker C; Feinstein MC; Delalonde L; Talbi M; Maloche C
J Clin Endocrinol Metab; 1996 Apr; 81(4):1460-4. PubMed ID: 8636351
[TBL] [Abstract][Full Text] [Related]
39. Importance of estrogen sulfates in breast cancer.
Pasqualini JR; Gelly C; Nguyen BL; Vella C
J Steroid Biochem; 1989; 34(1-6):155-63. PubMed ID: 2560511
[TBL] [Abstract][Full Text] [Related]
40. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
